ketorolac tromethamine + lidocaine hydrochloride

This investigational intranasal formulation combines 30 mg of ketorolac tromethamine with lidocaine hydrochloride (at concentrations of 4%, 5%, or 6%). Developed by Egalet Ltd, the product is designed for acute pain management. Ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) that provides systemic analgesia by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. Lidocaine hydrochloride is included as a local anesthetic to mitigate the nasal stinging and discomfort typically associated with intranasal ketorolac administration, thereby improving patient tolerability. A Phase 1 study demonstrated that the addition of lidocaine improved local tolerability and decreased the time to maximum plasma concentration of ketorolac without affecting peak concentration.

Other names

intranasal ketorolac tromethamine and lidocaine hydrochloride